Cargando…
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Strategies that enhance the function of T cells are critical for immunotherapy. One negative regulator of T-cell activity is ligand PD-L1, which is expressed on dentritic cells (DCs) or some tumor cells, and functions through binding of programmed death-1 (PD-1) receptor on activated T cells. Here w...
Autores principales: | Su, Shu, Hu, Bian, Shao, Jie, Shen, Bin, Du, Juan, Du, Yinan, Zhou, Jiankui, Yu, Lixia, Zhang, Lianru, Chen, Fangjun, Sha, Huizi, Cheng, Lei, Meng, Fanyan, Zou, Zhengyun, Huang, Xingxu, Liu, Baorui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730182/ https://www.ncbi.nlm.nih.gov/pubmed/26818188 http://dx.doi.org/10.1038/srep20070 |
Ejemplares similares
-
Corrigendum: CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
por: Su, Shu, et al.
Publicado: (2017) -
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells for adoptive therapy
por: Su, Shu, et al.
Publicado: (2015) -
iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
por: Ding, Naiqing, et al.
Publicado: (2019) -
Lipid insertion enables targeted functionalization of paclitaxel-loaded erythrocyte membrane nanosystem by tumor-penetrating bispecific recombinant protein
por: Chen, Hong, et al.
Publicado: (2018) -
Disappearance of bone metastases in chemotherapy-resistant gastric cancer treated with antigen peptide-pulsed dendritic cell-activated cytotoxic T lymphocyte immunotherapy: A case report
por: Du, Juan, et al.
Publicado: (2018)